The relevance of pre-motor symptoms in Parkinsons disease

Expert Review of Neurotherapeutics

Volumn 15, Issue 10, 2015, Pages 1205-1217

  Visanji, Naomi ^a   Marras, Connie ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

alpha synuclein; autonomic dysfunction; constipation; depression; excessive daytime sleepiness; olfactory dysfunction; Parkinsons disease; pre motor; rem behaviour disorder

Indexed keywords

CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; HUMAN; META ANALYSIS (TOPIC); PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMELLING DISORDER; SYMPTOM; SYSTEMATIC REVIEW; VISUAL DISORDER; AUTONOMIC NERVOUS SYSTEM DISEASES; EARLY DIAGNOSIS; MOOD DISORDERS; OLFACTION DISORDERS; PATHOPHYSIOLOGY; SLEEP WAKE DISORDERS;

AUTONOMIC NERVOUS SYSTEM DISEASES; CONSTIPATION; EARLY DIAGNOSIS; HUMANS; MOOD DISORDERS; OLFACTION DISORDERS; PARKINSON DISEASE; SLEEP WAKE DISORDERS;

EID: 84942985497     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1083423     Document Type: Review

References (118)

1. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinsons disease: diagnosis and management. Lancet neurology 2006; 5 (3): 235-45
2. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119 (6): 689-702
3. Lloyd KG. CNS compensation to dopamine neuron loss in Parkinsons disease. Adv Exp Med Biol 1977; 90: 255-66
4. Goldman JG, Postuma R. Premotor and nonmotor features of Parkinsons disease. Curr Opin Neurol 2014; 27 (4): 434-41
5. Del Tredici K, Braak H. Lewy pathology and neurodegeneration in premotor Parkinsons disease. Mov Disord 2012; 27 (5): 597-607
6. Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinsons disease (the ONSET PD study). Mov Disord 2015; 30 (2): 229-37
7. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68 (5): 384-6
8. Spillantini MG, Crowther RA, Jakes R, et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinsons disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998; 95 (11): 6469-73
9. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinsons disease-related pathology. Cell Tissue Res 2004; 318 (1): 121-34
10. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinsons disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110 (5): 517-36
11. Braak H, Sastre M, Bohl JR, et al. Parkinsons disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007; 113 (4): 421-9
12. Braak H, Rub U, Jansen Steur EN, et al. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64 (8): 1404-10
13. Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinsons disease. Mov Disord 2014; 29 (4): 454-62
14. Visanji NP, Brooks PL, Hazrati LN, Lang AE. The prion hypothesis in Parkinsons disease: Braak to the future. Acta Neuropathol Commun 2013; 1 (1): 2
15. Fasano A, Visanji NP, Liu LW, et al. Gastrointestinal dysfunction in Parkinsons disease. Lancet neurology 2015; 14 (6): 625-39
16. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007; 22 (11): 1581-6
17. Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology 2009; 73 (21): 1752-8
18. Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinsons disease. Am J Epidemiol 2011; 174 (5): 546-51
19. Postuma RB, Gagnon JF, Pelletier A, Montplaisir J. Prodromal autonomic symptoms and signs in Parkinsons disease and dementia with Lewy bodies. Mov Disord 2013; 28 (5): 597-604
20. Visanji NP, Marras C, Hazrati LN, et al. Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinsons disease biomarker. Mov Disord 2013
21. Hawkes CH, Del Tredici K, Braak H. Parkinsons disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33 (6): 599-614
22. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinsons disease. Mov Disord 2012; 27 (6): 709-15
23. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinsons disease and its relationship with symptoms. PLoS One 2010; 5 (9): e12728
24. Shannon KM, Keshavarzian A, Dodiya HB, et al. Is alpha-synuclein in the colon a biomarker for premotor Parkinsons disease? Evidence from 3 cases. Mov Disord 2012; 27 (6): 716-19
25. Olanow CW. A colonic biomarker of Parkinsons disease? Mov Disord 2012; 27 (6): 674-6
26. Gold A, Turkalp ZT, Munoz DG. Enteric alpha-synuclein expression is increased in Parkinsons disease but not Alzheimers disease. Mov Disord 2013; 28 (2): 237-40
27. Böttner M, Zorenkov D, Hellwig I, et al. Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol Dis 2012; 48 (3): 474-80
28. Visanji NP, Marras C, Kern DS, et al. Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 2015; 84 (6): 609-16
29. Adler CH, Dugger BN, Hinni ML, et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 2014; 82 (10): 858-64
30. Beach TG, Adler CH, Dugger BN, et al. Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 2013; 72 (2): 130-6
31. Schenck CH, Montplaisir JY, Frauscher B, et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy-a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med 2013; 14 (8): 795-806
32. Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet neurology 2006; 5 (7): 572-7
33. Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009; 72 (15): 1296-300
34. Boot BP, Boeve BF, Roberts RO, et al. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Ann Neurol 2012; 71 (1): 49-56
35. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46 (2): 388-93
36. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 2013; 14 (8): 744-8
37. Boeve BF, Silber MH, Ferman TJ, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013; 14 (8): 754-62
38. Peever J, Luppi PH, Montplaisir J. Breakdown in REM sleep circuitry underlies REM sleep behavior disorder. Trends Neurosci 2014; 37 (5): 279-88
39. Postuma RB, Gagnon JF, Vendette M, et al. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov Disord 2008; 23 (12): 1665-72
40. Postuma RB, Gagnon JF, Vendette M, et al. REM sleep behaviour disorder in Parkinsons disease is associated with specific motor features. J Neurol Neurosurg Psychiatry 2008; 79 (10): 1117-21
41. Gagnon JF, Vendette M, Postuma RB, et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinsons disease. Ann Neurol 2009; 66 (1): 39-47
42. Postuma RB, Gagnon JF, Vendette M, et al. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 2011; 69 (5): 811-18
43. Postuma RB, Gagnon JF, Tuineaig M, et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep 2013; 36 (11): 1579-85
44. Postuma RB, Gagnon JF, Montplaisir J. Rapid eye movement sleep behavior disorder as a biomarker for neurodegeneration: the past 10 years. Sleep Med 2013; 14 (8): 763-7
45. Postuma RB, Gagnon JF, Montplaisir JY. REM Sleep Behavior Disorder and Prodromal Neurodegeneration-Where Are We Headed? Tremor and other hyperkinetic movements (New York, N.Y.) 2013; 3
46. Postuma RB, Lang AE, Gagnon JF, et al. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 2012; 135 (Pt 6): 1860-70
47. Postuma RB, Gagnon JF, Bertrand JA, et al. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015; 84 (11): 1104-13
48. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinsons disease. Clin Neuropharmacol 1988; 11 (6): 512-19
49. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinsons disease. Mov Disord 1990; 5 (4): 280-5
50. van Hilten JJ, Weggeman M, van der Velde EA, et al. Sleep, excessive daytime sleepiness and fatigue in Parkinsons disease. Journal of neural transmission Parkinsons disease and dementia section 1993; 5 (3): 235-44
51. Fabbrini G, Barbanti P, Aurilia C, et al. Excessive daytime somnolence in Parkinsons disease. Follow-up after 1 year of treatment. Neurol Sci 2003; 24 (3): 178-9
52. Fabbrini G, Barbanti P, Aurilia C, et al. Excessive daytime sleepiness in de novo and treated Parkinsons disease. Mov Disord 2002; 17 (5): 1026-30
53. Hoglund A, Broman JE, Palhagen S, et al. Is excessive daytime sleepiness a separate manifestation in Parkinsons disease? Acta neurologica Scandinavica 2015. [Epub ahead of print]
54. Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinsons disease: the impact of nonmotor symptoms. Mov Disord 2014; 29 (2): 195-202
55. Doty RL, Stern MB, Pfeiffer C, et al. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinsons disease. J Neurol Neurosurg Psychiatry 1992; 55 (2): 138-42
56. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinsons disease. J Neurol Neurosurg Psychiatry 1997; 62 (5): 436-46
57. Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006; 21 (12): 2062-7
58. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinsons disease. Ann Neurol 2008; 63 (2): 167-73
59. Berg D, Godau J, Seppi K, et al. The PRIPS study: screening battery for subjects at risk for Parkinsons disease. Eur J Neurol 2013; 20 (1): 102-8
60. Ponsen MM, Stoffers D, Wolters E, et al. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinsons disease. J Neurol Neurosurg Psychiatry 2010; 81 (4): 396-9
61. Beach TG, White CL 3rd, Hladik CL, et al. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 2009; 117 (2): 169-74
62. Parkkinen L, Silveira-Moriyama L, Holton JL, et al. Can olfactory bulb biopsy be justified for the diagnosis of Parkinsons disease? Comments on "olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders". Acta Neuropathol 2009; 117 (2): 213-14
63. Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinsons disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21 (2): 148-58
64. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinsons disease. Mov Disord 2008; 23 (2): 183-9
65. Kim KY, Hershey LA. Diagnosis and treatment of depression in the elderly. Int J Psychiatry Med 1988; 18 (3): 211-21
66. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinsons disease. Mov Disord 2009; 24 (11): 1641-9
67. OSullivan SS, Williams DR, Gallagher DA, et al. Nonmotor symptoms as presenting complaints in Parkinsons disease: a clinicopathological study. Mov Disord 2008; 23 (1): 101-6
68. Fang F, Xu Q, Park Y, et al. Depression and the subsequent risk of Parkinsons disease in the NIH-AARP Diet and Health Study. Mov Disord 2010; 25 (9): 1157-62
69. Leentjens AF, Van den Akker M, Metsemakers JF, et al. Higher incidence of depression preceding the onset of Parkinsons disease: a register study. Mov Disord 2003; 18 (4): 414-18
70. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinsons disease: a case-control study. Mov Disord 2000; 15 (4): 669-77
71. Weisskopf MG, Chen H, Schwarzschild MA, et al. Prospective study of phobic anxiety and risk of Parkinsons disease. Mov Disord 2003; 18 (6): 646-51
72. Bower JH, Grossardt BR, Maraganore DM, et al. Anxious personality predicts an increased risk of Parkinsons disease. Mov Disord 2010; 25 (13): 2105-13
73. Orimo S, Uchihara T, Nakamura A, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinsons disease. Brain 131 (Pt 3): 642-50
74. Miki Y, Mori F, Wakabayashi K, et al. Incidental Lewy body disease restricted to the heart and stellate ganglia. Mov Disord 2009; 24 (15): 2299-301
75. Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinsons disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 2012; 18 (5): 494-500
76. Treglia G, Cason E, Stefanelli A, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clinical autonomic research: official journal of the Clinical Autonomic Research Society 2012; 22 (1): 43-55
77. Spiegel J, Hellwig D, Jost WH, et al. Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinsons Disease. The open neurology journal 2007; 1: 1-4
78. Oka H, Toyoda C, Yogo M, Mochio S. Reduced cardiac 123I-MIBG uptake reflects cardiac sympathetic dysfunction in de novo Parkinsons disease. J Neural Transm 2011; 118 (9): 1323-7
79. Chiaravalloti A, Stefani A, Di Biagio D, et al. Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinsons disease. Ann Nucl Med 2013; 27 (5): 444-51
80. Chiaravalloti A, Stefani A, Pierantozzi M, et al. Does 123I-MIBG scintigraphy really assist the diagnosis of Parkinsons disease? Parkinsonism Relat Disord 2013; 19 (8): 772-3
81. Kurata T, Kametaka S, Ohta Y, et al. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage. Internal medicine (Tokyo, Japan) 2011; 50 (22): 2775-81
82. Sawada H, Oeda T, Yamamoto K, et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 2009; 16 (2): 174-82
83. Uchiyama Y, Momose M, Kondo C, et al. Comparison of parameters of (123)I-metaiodobenzylguanidine scintigraphy for differential diagnosis in patients with parkinsonism: correlation with clinical features. Ann Nucl Med 2011; 25 (7): 478-85
84. Tijero B, Gomez-Esteban JC, Lezcano E, et al. Cardiac sympathetic denervation in symptomatic and asymptomatic carriers of the E46K mutation in the alpha synuclein gene. Parkinsonism Relat Disord 2013; 19 (1): 95-100
85. Tijero B, Gomez-Esteban JC, Llorens V, et al. Cardiac sympathetic denervation precedes nigrostriatal loss in the E46K mutation of the alpha-synuclein gene (SNCA). Clinical autonomic research: official journal of the Clinical Autonomic Research Society 2010; 20 (4): 267-9
86. Sakakibara R, Tateno F, Kishi M, et al. G myocardial scintigraphy in pre-motor Parkinsons disease: a review. Parkinsonism Relat Disord 2014; 20 (3): 267-73
87. Tateno F, Sakakibara R, Kishi M, et al. Constipation and metaiodobenzylguanidine myocardial scintigraphy abnormality. J Am Geriatr Soc 2012; 60 (1): 185-7
88. Courbon F, Brefel-Courbon C, Thalamas C, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinsons disease. Mov Disord 2003; 18 (8): 890-7
89. Low PA. Prevalence of orthostatic hypotension. Clin Auto Res 2008; 18 (Suppl 1): 8-13
90. Fumimura Y, Ikemura M, Saito Y, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease. J Neuropathol Exp Neurol 2007; 66 (5): 354-62
91. Wali GM. Parkinsonism associated with Addisons disease. Mov Disord 2003; 18 (3): 340-2
92. Goldstein DS. Orthostatic hypotension as an early finding in Parkinsons disease. Clin Auto Res 2006; 16 (1): 46-54
93. Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis 2012; 46 (3): 572-80
94. Kallio M, Haapaniemi T, Turkka J, et al. Heart rate variability in patients with untreated Parkinsons disease. Eur J Neurol 2000; 7 (6): 667-72
95. Valappil RA, Black JE, Broderick MJ, et al. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinsons disease. Mov Disord 2010; 25 (14): 2296-303
96. Postuma RB, Lanfranchi PA, Blais H, et al. Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. Mov Disord 2010; 25 (14): 2304-10
97. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinsons disease. Neurology 1992; 42 (4): 887-90
98. Lin TP, Rigby H, Adler JS, et al. Abnormal visual contrast acuity in Parkinsons disease. Journal of Parkinsons disease 2015; 5 (1): 125-30
99. Blekher T, Weaver M, Rupp J, et al. Multiple step pattern as a biomarker in Parkinson disease. Parkinsonism Relat Disord 2009; 15 (7): 506-10
100. Bodis-Wollner I, Kozlowski PB, Glazman S. Miri S. alpha-synuclein in the inner retina in parkinson disease. Ann Neurol 2014; 75 (6): 964-6
101. Miri S, Shrier EM, Glazman S, et al. The avascular zone and neuronal remodeling of the fovea in Parkinson disease. Ann Clin Translat Neurol 2015; 2 (2): 196-201
102. Hajee ME, March WF, Lazzaro DR, et al. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol (Chicago, IL; 1960) 2009; 127 (6): 737-41
103. Aaker GD, Myung JS, Ehrlich JR, et al. Detection of retinal changes in Parkinsons disease with spectral-domain optical coherence tomography. Clin Ophthalmol (Auckland, NZ) 2010; 4: 1427-32
104. Bodis-Wollner I. Retinopathy in Parkinson Disease. J Neural Transm 2009; 116 (11): 1493-501
105. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinsons disease. Brain 2009; 132 (Pt 5): 1128-45
106. Morris J, Brien D, Coe B, et al. Using eye movements to identify early biomarkers of disease progression in Parkinsons patients with and without LRRK2 gene mutations. In: Society for Neuroscience. Chicago, IL, USA: 2015
107. Marras C, Schuele B, Munhoz RP, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011; 77 (4): 325-33
108. Berg D, Seppi K, Behnke S, et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 2011; 68 (7): 932-7
109. Gaenslen A, Wurster I, Brockmann K, et al. Prodromal features for Parkinsons disease-baseline data from the TREND study. Eur J Neurol 2014; 21 (5): 766-72
110. Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology 2014; 83 (19): 1739-46
111. Healy DG, Falchi M, OSullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinsons disease: a case-control study. Lancet neurology 2008; 7 (7): 583-90
112. Kalia LV, Lang AE, Hazrati LN, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 2015; 72 (1): 100-5
113. Reijnders JS, Ehrt U, Lousberg R, et al. The association between motor subtypes and psychopathology in Parkinsons disease. Parkinsonism Relat Disord 2009; 15 (5): 379-82
114. Kumru H, Santamaria J, Tolosa E, Iranzo A. Relation between subtype of Parkinsons disease and REM sleep behavior disorder. Sleep Med 2007; 8 (7-8): 779-83
115. Stern MB, Doty RL, Dotti M, et al. Olfactory function in Parkinsons disease subtypes. Neurology 1994; 44 (2): 266-8
116. Erro R, Picillo M, Amboni M, et al. Nonmotor predictors for levodopa requirement in de novo patients with Parkinsons disease. Mov Disord 2015; 30 (3): 373-8
117. Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 2008; 116 (1): 1-16
118. Beach TG, Adler CH, Lue L, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009; 117 (6): 613-34